AtomVie Global Radiopharma
Buffalo, United States· Est.
A leading radiopharma CDMO delivering end‑to‑end cGMP manufacturing and supply for next‑generation theranostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $40M
AI Company Overview
A leading radiopharma CDMO delivering end‑to‑end cGMP manufacturing and supply for next‑generation theranostics.
OncologyDiagnostics
Technology Platform
cGMP radiopharmaceutical manufacturing with expertise in radiolabeling using isotopes such as Lu‑177, Ac‑225, I‑131, In‑111, and Zr‑89 for small molecules, peptides, and antibodies.
Opportunities
Expansion of commercial manufacturing capacity and increasing demand for theranostic radiopharmaceuticals present strong growth potential.
Risk Factors
Regulatory approval timelines, isotope supply chain constraints, and competition from established radiopharma CDMOs could impact execution.
Competitive Landscape
AtomVie competes with CDMOs such as Nordion, IBA, and Lantheus, differentiating through its integrated cGMP platform and early‑stage therapeutic collaborations.